Key result
Subcutaneous bococizumab achieves ~57% LDL-C reduction regardless of injection site.
RCT (n=75)
1:1:1
Answers are grounded in this paper and cite their sources.
Summary Aim To characterize the single‐dose pharmacokinetics ( PK ) and pharmacodynamics ( PD ) of bococizumab, a monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 ( PCSK 9), administered subcutaneously (s.c.) to the abdomen, thigh, or upper arm ( NCT 02043301). Methods Seventy‐five adults with low‐density lipoprotein cholesterol ( LDL ‐C) ≥130 mg/ dL and not on background lipid‐lowering therapy were randomized (1:1:1) to a single 150‐mg s.c. dose of bococizumab administered to the abdomen, thigh, or upper arm. Blood samples for bococizumab and lipids were collected for 12 weeks postdose. Results Plasma bococizumab concentration‐time profiles and PK parameters were generally similar across injection sites. Mean maximum observed concentration ( C max ) ranged from 8.14 to 11.9 μg/ mL , and area under the concentration‐time curve ( AUC inf ) ranged from 160.3 to 198.9 µg∙day/mL. The median time to C max ( T max ) ranged from 4.25 to 6.93 days. Similar LDL ‐C concentration‐time profiles were observed across injection sites, with mean (% coefficient of variation) maximum reductions in LDL ‐C of −57.5% (15.8), −57.0% (25.9), and −55.0% (24.1) for the abdomen, thigh, and upper arm, respectively. Adverse events ( AE s) were mostly mild and generally similar across injection sites. Commonly reported AE s were upper respiratory tract infection (9.3%), headache (6.7%), and injection site reaction (6.7%). One serious AE was reported (ischemic colitis), which was not considered related to study drug. Conclusions Similar PK profiles and robust LDL ‐C reductions were observed following a single 150‐mg s.c. injection of bococizumab administered to the abdomen, thigh, or upper arm in untreated subjects with LDL ‐C ≥130 mg/ dL . Bococizumab was generally well tolerated following a single 150‐mg s.c. administration in this subject population.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) conducted an RCT in Hypercholesterolemia (LDL-C >=130 mg/dL) (n=75). Bococizumab (subcutaneous injection to abdomen, thigh, or upper arm) vs. Comparison across three subcutaneous injection sites (abdomen, thigh, upper arm) was evaluated on Single-dose pharmacokinetics (Cmax, AUCinf, Tmax) and pharmacodynamics (maximum reduction in LDL-C). Bococizumab s.c. yielded similar PK profiles and max LDL-C reductions across abdomen, thigh, and upper arm injection sites.
Synapse has enriched 10 related papers. Consider them for comparative context: